194 related articles for article (PubMed ID: 31898331)
1. Preservation of Epstein-Barr virus status and mismatch repair protein status along the metastatic course of gastric cancer.
Dislich B; Blaser N; Berger MD; Gloor B; Langer R
Histopathology; 2020 Apr; 76(5):740-747. PubMed ID: 31898331
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus positivity, not mismatch repair-deficiency, is a favorable risk factor for lymph node metastasis in submucosa-invasive early gastric cancer.
Park JH; Kim EK; Kim YH; Kim JH; Bae YS; Lee YC; Cheong JH; Noh SH; Kim H
Gastric Cancer; 2016 Oct; 19(4):1041-1051. PubMed ID: 26573601
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study.
Hewitt LC; Inam IZ; Saito Y; Yoshikawa T; Quaas A; Hoelscher A; Bollschweiler E; Fazzi GE; Melotte V; Langley RE; Nankivell M; Cunningham D; Allum W; Hutchins GG; Grabsch HI
Eur J Cancer; 2018 May; 94():104-114. PubMed ID: 29550565
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
Zhang L; Wang Y; Li Z; Lin D; Liu Y; Zhou L; Wang D; Wu A; Li Z
Diagn Pathol; 2021 May; 16(1):38. PubMed ID: 33933102
[TBL] [Abstract][Full Text] [Related]
5. [Association of status of mismatch repair protein expression and EB virus infection with clinicopathological parameters in 886 gastric adenocarcinoma patients].
Liu Y; Zang FL; Qiu ZQ; Guo YH; Luo Y; Sun L; Zhao S; Shao B; Liang H; Sun Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):440-448. PubMed ID: 34000774
[No Abstract] [Full Text] [Related]
6. Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.
Kawazoe A; Shitara K; Kuboki Y; Bando H; Kojima T; Yoshino T; Ohtsu A; Ochiai A; Togashi Y; Nishikawa H; Doi T; Kuwata T
Gastric Cancer; 2019 Jan; 22(1):69-76. PubMed ID: 29859006
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
Pereira MA; Ramos MFKP; Faraj SF; Dias AR; Yagi OK; Zilberstein B; Cecconello I; Alves VAF; de Mello ES; Ribeiro U
J Surg Oncol; 2018 Apr; 117(5):829-839. PubMed ID: 29534305
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
[TBL] [Abstract][Full Text] [Related]
10. Gastric Carcinomas With Lymphoid Stroma: An Evaluation of the Histopathologic and Molecular Features.
Hissong E; Ramrattan G; Zhang P; Zhou XK; Young G; Klimstra DS; Shia J; Fernandes H; Yantiss RK
Am J Surg Pathol; 2018 Apr; 42(4):453-462. PubMed ID: 29438172
[TBL] [Abstract][Full Text] [Related]
11. Should you repeat mismatch repair testing in cases of tumour recurrence? An evaluation of repeat mismatch repair testing by the use of immunohistochemistry in recurrent tumours of the gastrointestinal and gynaecological tracts.
Aird JJ; Steel MJ; Chow C; Ho J; Wolber R; Gilks CB; Hoang LN; Schaeffer DF
Histopathology; 2020 Mar; 76(4):521-530. PubMed ID: 31677289
[TBL] [Abstract][Full Text] [Related]
12. Loss of ARID1A Expression is Related to Gastric Cancer Progression, Epstein-Barr Virus Infection, and Mismatch Repair Deficiency.
Han N; Kim MA; Lee HS; Kim WH
Appl Immunohistochem Mol Morphol; 2016; 24(5):320-5. PubMed ID: 26067140
[TBL] [Abstract][Full Text] [Related]
13. CDX-1/CDX-2 Expression Is a Favorable Prognostic Factor in Epstein-Barr Virus-Negative, Mismatch Repair-Proficient Advanced Gastric Cancers.
Kim K; Noh S; Cheong JH; Kim H
Gut Liver; 2021 Sep; 15(5):694-704. PubMed ID: 34312322
[TBL] [Abstract][Full Text] [Related]
14. Morphological evidence of an activated cytotoxic T-cell infiltrate in EBV-positive gastric carcinoma preventing lymph node metastases.
van Beek J; zur Hausen A; Snel SN; Berkhof J; Kranenbarg EK; van de Velde CJ; van den Brule AJ; Middeldorp JM; Meijer CJ; Bloemena E
Am J Surg Pathol; 2006 Jan; 30(1):59-65. PubMed ID: 16330943
[TBL] [Abstract][Full Text] [Related]
15. Subtraction of Epstein-Barr virus and microsatellite instability genotypes from the Lauren histotypes: Combined molecular and histologic subtyping with clinicopathological and prognostic significance validated in a cohort of 1,248 cases.
Huang SC; Ng KF; Yeh TS; Cheng CT; Lin JS; Liu YJ; Chuang HC; Chen TC
Int J Cancer; 2019 Dec; 145(12):3218-3230. PubMed ID: 30771224
[TBL] [Abstract][Full Text] [Related]
16. Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epstein-Barr virus infection and high- and low-microsatellite instability.
Kohlruss M; Grosser B; Krenauer M; Slotta-Huspenina J; Jesinghaus M; Blank S; Novotny A; Reiche M; Schmidt T; Ismani L; Hapfelmeier A; Mathias D; Meyer P; Gaida MM; Bauer L; Ott K; Weichert W; Keller G
J Pathol Clin Res; 2019 Oct; 5(4):227-239. PubMed ID: 31206244
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy.
Kim HS; Shin SJ; Beom SH; Jung M; Choi YY; Son T; Kim HI; Cheong JH; Hyung WJ; Noh SH; Chung H; Park JC; Shin SK; Lee SK; Lee YC; Koom WS; Lim JS; Chung HC; Rha SY; Kim H
Oncotarget; 2016 Jul; 7(28):44608-44620. PubMed ID: 27331626
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.
Bai Y; Xie T; Wang Z; Tong S; Zhao X; Zhao F; Cai J; Wei X; Peng Z; Shen L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35241494
[TBL] [Abstract][Full Text] [Related]
19. Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines.
Chang AMV; Chiosea SI; Altman A; Pagdanganan HA; Ma C
Head Neck Pathol; 2017 Jun; 11(2):203-211. PubMed ID: 27807760
[TBL] [Abstract][Full Text] [Related]
20. [Pathological Types,Expression of Mismatch Repair Protein,Human Epidermal Growth Factor Receptor 2,and Pan-TRK,and Eostein-Barr Virus Infection in Patients With Colorectal Cancer Resected in Tibet].
Luo HH; Huo Z; BIANbazhaxi ; Wang Q; DUObula ; NImazhuoma ; DA Z; Guo PP
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Jun; 45(3):422-428. PubMed ID: 37407529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
